<DOC>
	<DOCNO>NCT02345850</DOCNO>
	<brief_summary>The study design three arm randomize Phase III , multicenter trial compare two calcineurin inhibitor ( CNI ) -free strategy Graft-versus-Host Disease ( GVHD ) prophylaxis standard tacrolimus methotrexate ( Tac/Mtx ) patient hematologic malignancy undergo myeloablative conditioning hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Calcineurin Inhibitor-Free Interventions Prevention Graft-versus-Host Disease ( BMT CTN 1301 )</brief_title>
	<detailed_description>Chronic Graft-versus-Host Disease ( GVHD ) complication affect many hematopoietic stem cell transplant ( HSCT ) survivor ; occur new cell transplant attack recipient 's body . The current standard GVHD prophylaxis regimen patient hematologic malignancy undergo HSCT involve combination immunosuppressive agent give first 6 month transplant . Often , patient develop GVHD continue agent much long period . The combination calcineurin inhibitor ( tacrolimus cyclosporine A ) methotrexate ( MTX ) common GVHD prophylaxis use worldwide context myeloablative conditioning transplant . This regimen demonstrate well control acute GVHD , less effective chronic GVHD . Management chronic GVHD remain challenge become significant health problem transplant survivor frequent use mobilize peripheral blood stem cell . Additionally , several issue arise standard approach include various toxicity symptom side effect , increase risk thrombotic microangiopathy due CNI , prevention infectious disease , prevention disease relapse . This standard strategy Tac/MTX use control comparison two treatment plan utilizing CNI-free method : CD34 select T-cell depletion peripheral blood stem cell ( PBSC ) graft , infusion bone marrow ( BM ) graft follow post-transplant Cyclophosphamide ( PTCy ) . Study participant randomize one three treatment arm .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Males female age &gt; 1.0 year &lt; 66.0 year 2 . Patients acute leukemia morphologic complete remission myelodysplasia ( MDS ) circulate blast le 5 % blast bone marrow . Patients Chronic Myelomonocytic Leukemia ( CMML ) must white blood cell count ≤10,000 cells/µL &lt; 5 % blast marrow . 3 . Planned myeloablative conditioning regimen 4 . Patients must relate unrelated donor follow : 1 . Related donor must 8/8 match human leukocyte antigen ( HLA ) A , B , C intermediate ( high ) resolution , DRB1 high resolution use DNAbased typing . Pediatric related donor must weigh ≥ 25.0 kg. , must adequate peripheral venous catheter access leukapheresis must agree placement central catheter , must willing ( 1 ) donate bone marrow ( 2 ) receive GCSF follow donation peripheral blood stem cell ( product determine randomization post enrollment ) must meet institutional criterion donation . 2 . Unrelated donor must 8/8 match HLAA , B , C DRB1 high resolution use DNAbased typing . Unrelated donor must medically eligible donate accord National Marrow Donor Program ( NMDP ) ( equivalent donor search organization ) criterion . At time enrollment , donor know preference contraindication donate bone marrow peripheral blood stem cell . ( Selection unrelated donor perform accord institutional practice . It recommend time collection initiation cell processing consider prioritizing donor , data show well result CD34 selection cell processing begin within 36 hour end collection ) 5 . Cardiac function : Ejection fraction rest ≥ 45.0 % shorten fraction ≥ 27.0 % echocardiogram radionuclide scan ( MUGA ) . 6 . Estimated creatinine clearance ( patient &gt; 12 year ) great 50.0 mL/minute ( use CockcroftGault formula actual body weight ) ; pediatric patient ( &gt; 1 year 12 year ) , Glomerular Filtration Rate ( GFR ) estimate updated Schwartz formula ≥ 90.0 mL/min/1.73 m^2 . If estimate creatinine clearance &lt; 90 mL/min/1.73 m^2 , renal function must measure 24hour creatinine clearance nuclear GFR , must &gt; 70.0 mL/min/1.73 m^2 . 7 . Pulmonary function : Diffusing capacity lung carbon monoxide ( DLCO ) ≥ 50 % ( adjust hemoglobin ) , forced expiratory volume one second ( FEV1 ) force vital capacity ( FVC ) ≥ 50 % ; child unable perform Pulmonary Function Tests ( PFTs ) due age developmental ability , must evidence dyspnea need supplemental oxygen , evidence O2 saturation ≥ 92 % room air . 8 . Liver function : total bilirubin &lt; 2x upper limit normal ( unless elevate bilirubin attribute Gilbert 's Syndrome ) alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) &lt; 2.5x upper limit normal . 9 . Signed informed consent . 1 . Prior autologous allogeneic hematopoietic stem cell transplant 2 . Karnofsky Lansky Performance Score &lt; 70 % 3 . Active central nervous system ( CNS ) involvement malignant cell 4 . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical improvement ) time enrollment 5 . Presence fluid collection ( ascites , pleural pericardial effusion ) interfere methotrexate clearance make methotrexate use contraindicate 6 . Patients seropositive HIV1 2 7 . Patients seropositive Human TLymphotrophic Virus ( HTLV ) I II 8 . Patients active Hepatitis B C viral replication polymerase chain reaction ( PCR ) 9 . Documented allergy iron dextran murine proteins 10 . Women pregnant ( positive serum urine βHCG ) breastfeed 11 . Females childbearing potential ( FCBP ) men sexual contact FCBP unwilling use 2 effective form birth control abstinence one year transplantation 12 . History uncontrolled autoimmune disease active treatment 13 . Patients prior malignancy , except resect nonmelanoma treat cervical carcinoma situ . Cancer treat curative intent ≥ 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow unless approve Protocol Officer one Protocol Chairs . 14 . Patient unable comply treatment protocol include appropriate supportive care , followup research test 15 . Planned posttransplant maintenance therapy except FLT3 inhibitor TKIs 16 . German center : Treatment know nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior enrollment , whichever longer , participation interventional clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute Leukemia</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>GVHD Prophylaxis</keyword>
	<keyword>Chronic GVHD</keyword>
</DOC>